GLAND - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 3.4
| Stock Code | GLAND | Market Cap | 26,330 Cr. | Current Price | 1,597 ₹ | High / Low | 2,131 ₹ |
| Stock P/E | 22.2 | Book Value | 610 ₹ | Dividend Yield | 1.13 % | ROCE | 15.8 % |
| ROE | 11.6 % | Face Value | 1.00 ₹ | DMA 50 | 1,742 ₹ | DMA 200 | 1,776 ₹ |
| Chg in FII Hold | -0.32 % | Chg in DII Hold | 0.36 % | PAT Qtr | 326 Cr. | PAT Prev Qtr | 302 Cr. |
| RSI | 33.1 | MACD | -47.5 | Volume | 39,366 | Avg Vol 1Wk | 94,466 |
| Low price | 1,200 ₹ | High price | 2,131 ₹ | PEG Ratio | -6.47 | Debt to equity | 0.00 |
| 52w Index | 42.6 % | Qtr Profit Var | 10.4 % | EPS | 71.0 ₹ | Industry PE | 27.2 |
📊 GLAND Pharma shows limited short-term swing trade potential. The RSI at 33.1 indicates oversold conditions, but MACD (-47.5) remains negative, suggesting weak momentum. Fundamentals are decent with a P/E of 22.2, strong book value (610 ₹), and zero debt. However, the PEG ratio (-6.47) signals growth concerns. The optimal entry price would be near support around 1,550–1,570 ₹. If already holding, consider exiting near resistance around 1,740–1,780 ₹ unless momentum improves.
✅ Positive
- Reasonable P/E (22.2) compared to industry average (27.2)
- Strong book value (610 ₹) relative to current price
- Debt-free balance sheet ensures financial stability
- Quarterly profit growth (PAT up from 302 Cr. to 326 Cr.)
- EPS of 71 ₹ supports earnings strength
⚠️ Limitation
- Weak technical indicators: RSI oversold, MACD negative
- Current price below both 50 DMA (1,742 ₹) and 200 DMA (1,776 ₹)
- Negative PEG ratio (-6.47) reflects growth concerns
- Decline in FII holdings (-0.32%)
📉 Company Negative News
- Weak momentum indicators suggest short-term downside risk
- Institutional investor confidence declining (FII holdings down)
📈 Company Positive News
- Quarterly profit growth of 10.4%
- DII holdings increased by 0.36%
- Dividend yield of 1.13% adds shareholder value
🏭 Industry
- Industry P/E at 27.2, slightly higher than GLAND’s 22.2, suggesting relative undervaluation
- Pharmaceutical sector demand remains resilient with long-term growth potential
🔎 Conclusion
GLAND Pharma is fundamentally stable with strong book value and zero debt, but technical weakness and growth concerns limit swing trade attractiveness. Entry around 1,550–1,570 ₹ is optimal, with exit near 1,740–1,780 ₹ if resistance holds. Long-term investors may continue holding due to sector resilience, while swing traders should remain cautious until momentum indicators turn positive.